Certara Divests Regulatory & Medical Writing Business for up to $135M to Sharpen Strategic Focus
CERT sits 21% above its 52-week low of $5.19.
Summary
Certara, Inc. is selling its Regulatory and Medical Writing business for up to $135 million, a strategic move to focus on its core Model-Informed Drug Development (MIDD) solutions.
Key Events · M&A and Partnerships · CERT
-
Strategic Divestiture Agreement
Certara entered a definitive agreement to sell its global medical writing and related regulatory services business to Veristat, LLC.
-
Significant Cash Consideration
The transaction includes $100 million in upfront cash, subject to adjustments, and up to $35 million in contingent earn-out payments, totaling up to $135 million.
-
Focus on Core Business
The divestiture is intended to sharpen Certara's strategic focus on its Model-Informed Drug Development (MIDD) and Clinical Intelligence solutions.
-
Material Business Segment Sold
The divested business generated $50 million in revenue and $17 million in adjusted EBITDA in 2025, representing a notable portion of the company's operations.
Analysis · CERT · Technology
Certara's agreement to sell its Regulatory and Medical Writing business for up to $135 million represents a significant strategic divestiture. This move aims to sharpen the company's focus on its core Model-Informed Drug Development (MIDD) and Clinical Intelligence solutions, aligning with its stated strategy to accelerate AI-integrated modeling and simulation. The transaction provides substantial capital that Certara intends to deploy for long-term value creation, and investors should monitor the updated 2026 guidance for the financial impact of this strategic shift.
At the time of this filing, CERT was trading at $6.30 on NASDAQ in the Technology sector, with a market capitalization of approximately $950.6M. The 52-week trading range was $5.19 to $15.38. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.